Medical Cannabis for Multiple Sclerosis: Managing Spasticity, Pain, and More

Multiple sclerosis (MS) is one of the conditions where medical cannabis has been studied most extensively, and it's one of the explicitly qualifying conditions under Florida's medical marijuana program. For patients dealing with the pain, spasticity, and sleep disruption that commonly accompany MS, cannabis offers a treatment avenue that addresses multiple symptoms through a single intervention.

Let me walk through what the evidence actually shows — because this is an area where the research is more developed than for many other conditions.

MS and the Endocannabinoid System

To understand why cannabis may help MS symptoms, it helps to know that your endocannabinoid system (ECS) is deeply involved in the processes that go wrong in multiple sclerosis.

The ECS regulates inflammation, immune response, nerve signal transmission, and muscle tone — all of which are disrupted in MS. Research has found that endocannabinoid levels are altered in MS patients, and CB1 and CB2 receptors are upregulated in areas of active disease. The body appears to be mounting its own cannabinoid response to the disease process, but it may not be producing enough endocannabinoids to be fully effective.

This provides a plausible biological rationale for supplementing with plant-derived cannabinoids.

Spasticity: The Strongest Evidence

Muscle spasticity — involuntary tightness, stiffness, and spasms — affects up to 80 percent of MS patients and is often one of the most limiting symptoms. It interferes with mobility, sleep, and daily function.

This is the MS symptom where cannabis research is most robust. Nabiximols (brand name Sativex), a pharmaceutical cannabis product containing a 1:1 ratio of THC and CBD, has been approved in over 25 countries specifically for MS-related spasticity. While Sativex itself is not FDA-approved in the United States, the research supporting it is directly relevant to whole-plant medical cannabis products available through Florida dispensaries.

Key findings from clinical studies:

• A large randomized controlled trial (the CAMS study) involving 630 MS patients found that cannabis extract improved patient-reported spasticity scores, with additional benefits for pain and sleep
• The MUSEC trial found that cannabis extract was nearly twice as likely to provide relief from muscle stiffness compared to placebo
• Long-term follow-up studies show that benefits are sustained over 12 months or more with continued use
• Patients who respond to an initial trial (roughly 40 to 50 percent) tend to maintain that response over time

The mechanism appears to involve THC's activation of CB1 receptors in the spinal cord and motor cortex, which directly modulates the neural circuits controlling muscle tone.

Pain in MS

Pain affects 50 to 80 percent of MS patients, and it takes multiple forms:

Neuropathic pain — burning, shooting, or electric-shock sensations caused by nerve damage. This is the most common type of MS-related pain and often the most difficult to treat with conventional medications.

Musculoskeletal pain — aching in muscles and joints, often secondary to spasticity, altered gait patterns, or reduced mobility.

Central pain — a direct result of lesions in pain-processing areas of the brain and spinal cord.

Conventional treatments for MS pain include gabapentin, pregabalin, duloxetine, and sometimes tricyclic antidepressants. These help some patients but often provide incomplete relief with significant side effects.

Cannabis addresses MS pain through several pathways:

• THC directly modulates pain signaling via CB1 receptors in the spinal cord and brain
• CBD provides anti-inflammatory and neuromodulatory effects
• Spasticity reduction indirectly reduces musculoskeletal pain
• Improved sleep from cannabis use supports the body's pain recovery processes

Multiple studies have shown statistically significant pain reduction in MS patients using cannabis, though the effect sizes are moderate — typically a 20 to 30 percent reduction in pain scores. This may sound modest in isolation, but when added to other treatments, it can make the difference between manageable and unmanageable pain.

Sleep Disruption

Sleep problems are extremely common in MS and are driven by pain, spasticity (particularly nocturnal spasms), bladder dysfunction, anxiety, and medication side effects. Poor sleep worsens fatigue — already a dominant MS symptom — creating a difficult cycle.

Cannabis, particularly THC-containing products taken in the evening, can improve multiple sleep parameters:

• Reduced time to fall asleep
• Fewer nocturnal awakenings from spasms or pain
• Increased total sleep duration
• Improved subjective sleep quality

For patients whose sleep is primarily disrupted by spasticity or pain, addressing those symptoms with cannabis naturally improves sleep as a secondary benefit.

Bladder Dysfunction

Bladder urgency, frequency, and incontinence affect roughly 75 percent of MS patients. While this isn't a primary indication for cannabis, some studies have shown modest improvements in bladder symptoms with cannabis use. CB1 receptors are present in the bladder wall and detrusor muscle, providing a plausible mechanism, though the evidence here is less established than for spasticity and pain.

Practical Treatment Approach for MS Patients

Getting Started

If you're an MS patient in Florida considering medical cannabis, here's a reasonable starting framework:

For spasticity and pain as primary complaints:

Start with a 1:1 THC:CBD tincture. This mirrors the ratio used in the most successful clinical trials. Begin with a low dose (2.5 mg each of THC and CBD) twice daily, and increase gradually every three to five days until you find the dose that provides meaningful relief without unacceptable side effects.

For sleep as the primary complaint:

An evening dose of a THC-dominant product (edible or tincture) taken 60 to 90 minutes before bed. Start with 2.5 to 5 mg of THC and adjust based on response.

For breakthrough spasms or acute pain:

Have an inhaled product available for rapid relief when spasms or pain flares occur unexpectedly. Vaporization provides onset within minutes.

Combining With Existing MS Treatments

Medical cannabis can be used alongside most MS disease-modifying therapies (DMTs). There are no known significant interactions between cannabis and interferons, glatiramer acetate, dimethyl fumarate, fingolimod, or natalizumab.

However, cannabis should be used cautiously with:

• Baclofen or tizanidine — cannabis and these muscle relaxants can have additive sedative effects. Start cannabis at a lower dose if you're already on these medications.
• Benzodiazepines — combined sedation and cognitive impairment. Reduction of the benzodiazepine may be possible if cannabis provides adequate spasticity and anxiety relief.
• Gabapentin/pregabalin — similar additive sedation risk. Gradual dose adjustment of either medication may be needed.

Always inform all of your treating physicians that you're using medical cannabis so they can account for potential interactions.

What to Monitor

Keep track of:

• Spasticity severity (use a daily 0-10 scale)
• Pain levels
• Number and severity of spasms, particularly at night
• Sleep quality and duration
• Fatigue levels
• Cognitive function — some MS patients report that THC worsens cognitive fog, while others notice no difference or even improvement (possibly through better sleep and pain control)
• Walking and balance — important to assess whether cannabis is affecting these positively or negatively

Important Considerations

Cognitive effects. MS itself causes cognitive changes in many patients. THC can affect memory and processing speed. For some patients, this is a meaningful concern. Using CBD-dominant products during the day and reserving THC for the evening is one strategy to minimize daytime cognitive impact.

Heat sensitivity. Many MS patients are heat-sensitive (Uhthoff's phenomenon). Be aware that smoking or vaporizing in hot environments may combine with heat sensitivity to worsen symptoms temporarily.

Progressive MS. Most cannabis research in MS has focused on relapsing-remitting MS. Patients with progressive forms may respond differently, and expectations should be adjusted accordingly. Cannabis may help manage symptoms even in progressive disease, but the evidence is less specific.

Cannabis is not a disease-modifying therapy. While there's preclinical research suggesting cannabinoids may have neuroprotective properties, there is no clinical evidence that cannabis slows MS progression. Continue your neurologist-prescribed DMT. Cannabis addresses symptom management, not disease modification.

Finding the Right Care

MS is complex, and adding medical cannabis to an existing treatment regimen requires thoughtful coordination. At Coral Health, we work with MS patients to integrate cannabis into their broader care plan, communicate with their neurology team as needed, and adjust treatment over time based on response.

If you're a Florida resident with MS and interested in exploring medical cannabis for symptom management, [schedule a consultation](/booking) to discuss whether it's appropriate for your situation.